ProBioGen and ValenzaBio have entered into a second service agreement.
 
Note: Read about ProBioGen and ValenzaBio’s previous pact.
 
The new project is a continuation of successfully completed cell line development work that utilized ProBioGen’s proprietary technologies. The new program includes upstream and downstream process development and large-scale GMP production. In addition, ProBioGen’s cell and tissue services department will develop several cell-based bioassays to thoroughly characterize the molecule. Under the previous license agreement, ProBioGen is eligible to receive milestone payments. Further financial details were not disclosed.
 
“We are excited to continue our collaboration with ProBioGen,” said Tatyana Touzova, chief operating officer of ValenzaBio. “As the leading experts in cell line development and originators of the GlymaxX technology, which offers the benefits of ADCC enhancement in mAb, ProBioGen continues to demonstrate its role as a key player in this industry. With the proficiency of ProBioGen’s manufacturing and bioanalytical teams, we are eager to advance the VB119 program to the commercial level.”
 
“We are happy to continue the journey with ValenzaBio. It shows again that our services and technologies as well as our high-quality work are successful. Supporting our clients on their way to the clinic in the best possible way is embedded in our mission to facilitate today the development of medicines for tomorrow − even for diseases that are not yet curable,” added Dr. Gabriele Schneider, ProBioGen’s chief business officer.